Statistics

Total Visits

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors100

Select a period of time:

Number of views in the range

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors34

Views

Views
December 20252
January 20261
February 20260
March 20264
April 20264
May 202616
June 20267
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States17
France2
United Kingdom2
Argentina2
Brazil1
Canada1
Germany1
Kenya1
Lithuania1
Morocco1
 

Top cities views

Views
Anderson1
Ashburn1
Atlanta1
Cape Town1
Des Moines1
Fes1
General Villegas1
Groningen1
Katueté1
Lima1